Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis - Review of the literature

European Journal of Medical Research

Volumn 16, Issue 4, 2011, Pages 139-144

  Sandherr, Michael ^a   Maschmeyer, Georg ^b  

^a Hematology and Oncology Specialized Practice   (Germany)

^b KLINIKUM ERNST VON BERGMANN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; AMPHOTERICIN B LIPID COMPLEX; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450; ERGOT ALKALOID; FAMOTIDINE; FLUCONAZOLE; GLUCURONOSYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; ITRACONAZOLE; OMEPRAZOLE; PHENYTOIN; POSACONAZOLE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; SILDENAFIL; SULFONYLUREA; TACROLIMUS; TERFENADINE; UNINDEXED DRUG; VINCA ALKALOID; VORICONAZOLE; AMPHOTERICIN B DEOXYCHOLATE; ATAZANAVIR; CIMETIDINE; CYTOCHROME P450 2C19; EFAVIRENZ; LORAZEPAM; METHADONE; MIDAZOLAM; PIMOZIDE; QUINIDINE; RANITIDINE; RITONAVIR; WARFARIN;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CANDIDEMIA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TRANSFORMATION; ESOPHAGUS CANDIDIASIS; FOOD; GENETIC POLYMORPHISM; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; OVERALL SURVIVAL; REVIEW; STOMACH PH; SURVIVAL RATE; SYSTEMIC MYCOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANTIFUNGAL SUSCEPTIBILITY; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DRUG ANTAGONISM; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ELIMINATION HALF-LIFE; FEBRILE NEUTROPENIA; FOOD DRUG INTERACTION; FUSARIOSIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPLASMOSIS; LUNG ASPERGILLOSIS; MINIMUM PLASMA CONCENTRATION; MUCORMYCOSIS; NONHUMAN; PHARMACODYNAMICS; PSEUDALLESCHERIASIS; VOLUME OF DISTRIBUTION;

EID: 79955825567     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-4-139     Document Type: Review

References (39)

1. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in haematopoietic stem cell recipients. Clin Infect Dis 2002; 34:909-17 (Pubitemid 34229758)
2. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematological malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75 (Pubitemid 44208634)
3. Cuenca-Estrella M, Bernal-Martinez I, Buitrago MJ et al. Update on the epidemiology and diagnosis of invasive fungal infections. Int J Antimicrob Agents 2008; 32(suppl2): S 143-7
4. Patterson TF. Advances and challenges in management of invasive mycosis. Lancet 2005; 366: 1013-25 (Pubitemid 41323037)
5. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003: 37(suppl3): S 157-87
6. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481-3
7. Boucher HW, Groll AH, Chiou CC et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-20
8. Purkins L, Wood N, Greenhalgh K et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 Suppl 1: 10-6 (Pubitemid 37491728)
9. Purkins L, Wood N, Kleinermans D, Greenhalgh K et al. Effect of food on the pharmacokinetics of multiple-dose oral Voriconazole. Br J Clin Pharmacol 2003; 56: 17-23 (Pubitemid 37491729)
10. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of Voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53 (Pubitemid 34793462)
11. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of Voriconazole. Drug Metab Dispos 2003; 31: 540-7 (Pubitemid 36444162)
12. Miyakis S, van Hal SJ, Ray J et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Infect Dis 2010; 16: 927-33
13. Bruggemann RJ, Blijlevens NM, Burger DM et al. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2010; 65: 107-13
14. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazol in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71 (Pubitemid 34165316)
15. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in haematopoietic stem cell recipients. Cancer 2007; 109: 1532-5 (Pubitemid 46595688)
16. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for determination of protein binding. In: Lorian V, editor. Antibiotics in laboratory medicine. Philadelphia (PA): Lippincott Williams & Wilkins 1991: 367-402.
17. Jeu L, Piacenti FJ, Lyakhovetskiy AG et al. Voriconazole. Clin Ther 2003; 25: 1321-81 (Pubitemid 36677282)
18. Ikeda Y, Umemura K, Kondo K et al. Pharmacokinetics of Voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-8 (Pubitemid 38746611)
19. Pfizer Inc. Label: Voriconazole for injections, tablets, oral suspension: LAB -0271-12; 2005 Mar
20. Drago M, Scaltrito MM, Morace G. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004; 23: 619-24
21. Gil-Lamaignere C, Hess R, Salvenmoser S. Effect of media composition and in vitro activity of Posaconazole, Caspofungin and Voriconazole against zygomycetes. J Antimicrob Chemother 2005; 55: 1016-9 (Pubitemid 40883191)
22. Walsh TJ, Anaissie EL, Denning DW et al. Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60
23. Herbrecht R, Denning DW, Patterson TF et al., Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15 (Pubitemid 34851833)
24. Wingard JL, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic haematopoietic cell transplantation. Blood 2010; 116: 5111-18
25. Smith JA. What is the role of therapeutic drug monitoring in antifungal therapy? Curr Infect Dis Rep 2009; 11: 439-46
26. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45: 1610-7 (Pubitemid 351411847)
27. Li Y, Theuretzbacher U, Clancy CJ et al. Pharmacokinetic/Pharmacodynamic profile of Posaconazole. Clin Pharmacokinet 2010 ; 49: 379-96
28. Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral Posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-95 (Pubitemid 37040249)
29. Ezzet F, Wexler D, Courtney R et al. Oral bioavailability of Posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211-20 (Pubitemid 40188942)
30. Schering-Plough Inc. Label: Noxafil® (Posaconazole) oral suspension. Labeling - 31029708. Kenilworth (NJ): Schering-Plough Inc., 2006 Oct
31. Wexler D, Courtney R, Richards W et al. Effect of Posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-53
32. Ghosal A, Hapangama N, Yuan Y et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil®). Drug Metab Dispos 2004; 32: 267-71
33. Courtney R, Wexler D, Radwanski E et al. Effect of food on the relative bioavailability of two oral formulations of Posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-22 (Pubitemid 38223535)
34. Courtney R, Radwanski E, Lim J et al. Pharmacokinetics of Posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48: 804-8 (Pubitemid 38280328)
35. Ullmann A, Lipton J, Vesole D et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47 (Pubitemid 46148776)
36. Cornely OA, Maertens J, Winston D et al. Posaconazole vs fluconazole or itraconazole prophylaxis for patients with neutropenia. N Engl J Med 2007; 356: 348-359 (Pubitemid 46148777)
37. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356: 409-11
38. van Burik JAH, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006: 42:e61-5
39. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trail. Clin Infect Dis 2007; 44: 2-12 (Pubitemid 44968977)